Intuitive Surgical, Inc. (ISRG)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.11% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded.
- Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside
- Intuitive Surgical is Down this Year Despite Double-Digit Growth. Is Its 33x Valuation Still Justified?
- ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?
- Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know
- Countdown to Intuitive Surgical (ISRG) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Zacks.com featured highlights include Chipotle Mexican Grill, BP and Intuitive Surgical
- ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Intuitive Surgical, Inc..
Full ISRG Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.